- Home
- DHAI vs OVID Comparison
DHAI vs OVID Comparison
Compare DHAI & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DHAI
- OVID
- Stock Information
- Founded
- DHAI 2007
- OVID 2014
- Country
- DHAI United States
- OVID United States
- Employees
- DHAI N/A
- OVID N/A
- Industry
- DHAI
- OVID Biotechnology: Pharmaceutical Preparations
- Sector
- DHAI
- OVID Health Care
- Exchange
- DHAI NYSE
- OVID Nasdaq
- Market Cap
- DHAI 49.1M
- OVID 47.1M
- IPO Year
- DHAI N/A
- OVID 2017
- Fundamental
- Price
- DHAI $0.22
- OVID $0.31
- Analyst Decision
- DHAI
- OVID Strong Buy
- Analyst Count
- DHAI 0
- OVID 6
- Target Price
- DHAI N/A
- OVID $3.03
- AVG Volume (30 Days)
- DHAI 597.4K
- OVID 406.6K
- Earning Date
- DHAI 02-14-2025
- OVID 03-11-2025
- Dividend Yield
- DHAI N/A
- OVID N/A
- EPS Growth
- DHAI N/A
- OVID N/A
- EPS
- DHAI N/A
- OVID N/A
- Revenue
- DHAI $69,573,000.00
- OVID $566,000.00
- Revenue This Year
- DHAI N/A
- OVID N/A
- Revenue Next Year
- DHAI N/A
- OVID $36.11
- P/E Ratio
- DHAI N/A
- OVID N/A
- Revenue Growth
- DHAI 5.40
- OVID 44.39
- 52 Week Low
- DHAI $0.22
- OVID $0.30
- 52 Week High
- DHAI $3.67
- OVID $3.45
- Technical
- Relative Strength Index (RSI)
- DHAI 28.55
- OVID 22.38
- Support Level
- DHAI $0.24
- OVID $0.42
- Resistance Level
- DHAI $0.28
- OVID $0.48
- Average True Range (ATR)
- DHAI 0.04
- OVID 0.05
- MACD
- DHAI 0.01
- OVID -0.01
- Stochastic Oscillator
- DHAI 2.28
- OVID 3.84
About DHAI DIH HOLDINGS US INC
DIH Holding US Inc is a provider of robotic devices used in physical rehabilitation, which incorporate visual stimulation in an interactive manner to enable clinical research and intensive functional rehabilitation and training in patients with walking impairments, reduced balance and/or impaired arm and hand functions. Its products Armeo Power, Armeo Spring, Armeo Spring Pro, etc.
About OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential in-class mechanism of action.